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Summary
QUESTIONS UNDER STUDY: To perform a cost-of-ill-
ness study of acute coronary syndrome (ACS) in Switzer-
land from a societal perspective, evaluating direct costs,
production losses and intangible costs in terms of quality
adjusted life years (QALYs) lost.
METHODS: A bottom-up incidence-based approach was
used. Data concerning patients with one or more ACS
events were extracted from a national hospital database
and from mortality statistics. Inpatient costs included acute
care and rehabilitation. Outpatient costs included costs for
ambulance, visits to GP and cardiologist, outpatient dia-
gnostics, medication and rehabilitation. Production losses
included absenteeism, permanent disability and premature
death. Intangible costs were calculated on previously pub-
lished QALY weights. Cost data were derived from official
price lists, literature and experts. Future costs and QALYs
lost were discounted.
RESULTS: In 2008 14,955 patients experienced a total of
16,815 ACS events; 2,752 died as a consequence of these.
The resulting 19,064 hospital stays had an average across-
hospital length of stay of 9.1 days per patient. Total direct
costs of ACS amounted to 630 Mio Swiss Francs (CHF)
for society and CHF 462 Mio for health insurers. Total dir-
ect costs were dominated by costs of myocardial infarction:
ST-elevation 45.8%, non-ST-elevation 35.8%. Production
losses were CHF 519 Mio and intangible costs resulted in
49,878 QALYs lost.
CONCLUSIONS: ACS causes considerable costs in terms
of direct medical expenditures, lost production, suffering
and premature death, even without taking into account
costs for its chronic consequences such as congestive heart
failure.
Key words: acute coronary syndrome; ACS; myocardial
infarction; cost; Switzerland; cost-of-illness; production
losses; intangible costs; QALY
Glossary of health economic terms (in part based on Berger et al. [1] and Culyer [2]).
AP-DRG A prospective payment system for inpatient care based on diagnosis and type of treatments. In 2008 approximately one third of
Swiss hospitals employed AP-DRG for reimbursement.
Bottom-up approach Analysis based on information on costs borne by single patients in a sample of the population or the total population.
Cost-of-illness (COI) study Measures the total economic burden of a disease as the maximum amount that could be saved if the disease were to be
eradicated.
Direct medical costs Costs occurring in the medical treatment of patients.
Discounting Method to adjust future costs and benefits to their present value.
GDP (gross domestic product) Total market value of all final goods and services produced in a country in a given year. Corresponds to total domestic income.
Intangible costs Amount of suffering and life years lost because of a disease or a health care intervention. Intangible cost corresponds to QALYs
lost.
Perspective Viewpoint adopted which defines the costs considered in a study. The societal perspective includes all costs regardless of who
bears them.
Production losses* Ability of patients to be part of the active working population temporarily reduced or permanently lost due to a disease. Production
losses correspond to income losses.
QALY (quality adjusted life year) Universal health outcome measure applicable to all diseases. A QALY combines gains and losses of quantity of life (mortality) and
quality of life (morbidity) in a single measure. A life year in full health has a QALY value of 1.
Sensitivity analysis Analysis of the impact of uncertainty on the results of a study.
* These costs are sometimes also called indirect costs or income losses. We prefer the term “production losses” because it best describes the type of economic loss
intended and because it is least prone to misunderstandings. The use of this terminology is also recommended in the latest edition of a widely used handbook on economic
evaluations in health care [3].
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Introduction
Coronary heart disease is the main cause of death in the
world and in middle- and high-income countries [4]. Acute
coronary syndrome (ACS), namely unstable angina pector-
is (UAP) and myocardial infarction (MI), is the most im-
portant clinical consequence of coronary heart disease.
Previous studies estimated direct costs and production
losses of ischaemic heart disease in Switzerland in 1987 [5]
and 1993 [6]. The results of these studies included the costs
of ACS without examining them separately. Moreover, the
pharmacological and interventional treatments of ACS
have changed substantially over the past two decades
[7–9]. For example, the rate of patients with percutaneous
coronary interventions (PCIs) has increased considerably
compared to thrombolysis. Furthermore, a more successful
secondary prevention of ACS may have resulted from the
establishment of new anti-thrombotic drugs, a rigorous lip-
id management with statins and new pharmacological
smoking cessation therapies. In addition, the length of stay
of patients has decreased in hospitals.
The economic impact of modern coronary reperfusion ther-
apies, quicker access to therapies and shorter hospital stays
have not been well assessed for Switzerland. One might as-
sume rising direct medical costs for ACS patients driven
by modern reperfusion therapies. From a societal perspect-
ive, however, this cost rise might be smaller than expected
due to reduced downstream costs and higher quality of life.
Thus, up-to-date cost of illness data can contribute valuable
information.
As the current total costs of ACS in Switzerland are not
known, we designed a cost-of-illness (COI) study of ACS
from a societal and a health insurance perspective includ-
ing direct medical costs, production losses and intangible
costs. A COI study is a descriptive analysis assessing the
economic burden of a disease on the population [10]. A
COI study can provide comparative health economic eval-
uations of new treatments (e.g. cost-effectiveness and cost-
utility studies) with important inputs on the cost conse-
List of abbreviations
ACS Acute coronary syndrome
AMI Acute myocardial infarction
AMIS Acute Myocardial Infarction in Switzerland
AP-DRG All Patient Diagnosis Related Groups
CHF Swiss Francs
COI Cause of Death Statistics (Todesursachenstatistik)
DeathStat T-cell receptor
EUR Euro
FSO Federal Office of Statistics (Bundesamt für Statistik)
GDP Gross domestic product
GP General practitioner
ICU Intensive care unit
MedStat Medical Statistics of Hospitals (Medizinische Statistik der
Krankenhäuser)
MI myocardial infarction
Mio Million
NSTEMI Non-ST-elevation myocardial infarction
PCI Percutaneous coronary intervention
QALY Quality adjusted life year
STEMI ST-elevation myocardial infarction
UAP Unstable angina pectoris
WHO World Health Organisation
quences of the disease. Assessing the benefits of new treat-
ments however is not part of a COI study.
Methods
The main objective of the study was the assessment of the
cost-of-illness of ACS in Switzerland occurring in 2008
(the most recent year for which the data was available) with
a bottom-up (person-based) approach. Costs of ACS in-
clude the follow-up costs of monitoring and medication for
the remaining lifetime of surviving ACS patients. All ACS
events (with the exception of heart failure) were considered
whether they were repeat or initial events. However, the
treatment of heart failure was not included as we did not
want to assess the cost of atherosclerosis as a whole. Pro-
duction losses were calculated to the patient’s expected age
of retirement, and intangible costs were calculated on life
expectancy.
The following sources were used to derive the relevant
data: Patient numbers on hospitalisation and mortality, in-
patient costs and information on production losses were
provided by the Swiss Federal Office of Statistic [11–16].
They cover all patients or inhabitants in Switzerland. Pa-
tient numbers attending outpatient rehabilitation come
from the Swiss ACS registry AMIS Plus [17]. Tariff data
on cardiac rehabilitation are from the Swiss health insurer
association [18]. Outpatient drug consumption was mod-
elled according to AMIS plus registry data [17] and a Ger-
Figure 1
Overview of ACS events and outpatient treatments considered.
The figure gives an overview of ACS events occurring in 2008 and
resulting treatments. All inpatient treatments in 2008 were
considered as well as outpatient treatments from ACS in 2008 until
death. Remaining life years of surviving patients were modelled on
age, gender and life expectancy statistics adjusted by a factor for
increased relative mortality risk after an ACS. Treatments
considered in the study are represented by bold icons and
continuous lines, treatments not considered by light icons and
broken lines. The study did not consider inpatient care provided in
2009 and following years (example 3) or possible outpatient
treatment before a 1st ACS event in 2008 (example 5).
Examples of sequences of ACS events:
1 – Death at 1st event in 2008 before reaching hospital.
2 – Hospital stay at 1st event in 2008 and death at 2nd event in
2008. Outpatient care between 1st event and death.
3 – Hospital stay at 1st event in 2008 and 2nd event in 2010 (not
considered in study). Outpatient care until death.
4 – 1st event in 2008: Sequence of 2 hospital stays. Outpatient
care until death.
5 – Hospital stay at 1st event in 2007 (not considered). Hospital
stay at 2nd event in 2008. Outpatient care until 2nd event in 2008
not considered. Outpatient care until death.
6 – Hospital stay at 1st event in 2006 and 2nd event in 2009 (both
not considered). Outpatient care from 1st event in 2006 until death
in 2010 not considered.
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man expert survey [19]. Use of other outpatient care re-
sources was modelled according to the German survey [19]
and adapted to the Swiss standard by expert interviews (a
private practice general practitioner and a private practice
cardiologists active in Winterthur, a mid-sized town in the
German speaking part of Switzerland).
The number of ACS patients was calculated with an
incidence-based approach consisting of two steps: 1) All
patients with one or more ACS events were identified in
the Medical Statistic of Hospitals (MedStat) [11] and the
Cause of Death Statistics (DeathStat) [12]. 2) Remaining
life years were modelled on average life expectancy [13].
These two statistics cover all hospital stays and all deaths
occurring in Switzerland and are thus highly representative.
We assumed a factor for increased relative risk of mortality
per year of 1.5 for the patients surviving an ACS. The
all-cause mortality risk per year of 2% of a 68 year old
man does for example increase to 3%. This assumption is
based on studies exploring the survival rates of MI patients
[20–25]. The consequences of variations of this assumption
were tested in the sensitivity analysis (1.0 for same mor-
tality risk as general population and 2.0 for twofold annual
mortality risk).
Patients with ACS events were identified by their ICD-10
main diagnosis (UAP: I20.0; NSTEMI: I21.4; I21.9; I22.9;
STEMI: I21.0; I21.1–3; I22.0–1; I22.8). Strokes which
may occur as adverse events in the treatment of ACS were
also considered (I60.1–9; I61.1–9; I62.0, 1,9; I63.1–9; I64)
in patients with ACS as secondary diagnosis if the stroke
event occurred during the ACS hospitalisation. According
to the MedStat coding handbook [26], the diagnosis to be
coded as main diagnosis in patients with several diagnoses
is the diagnosis that required the largest amount of medical
resources. As treatment of stroke requires more resources
than treatment of ACS, ACS with stroke as a major com-
plication should be coded with stroke as main diagnosis
and ACS as a secondary diagnosis.
The distinction between ACS patients and hospital stays
due to ACS is crucial in order to determine the true number
of ACS patients, as single hospital stays in different hospit-
als are often part of the same ACS event. Fortunately, the
MedStat makes it possible to attribute separate ACS events
to a single patient. Figure 1 gives an overview of possible
ACS events occurring in 2008 and subsequent treatments
considered in this study.
Inpatient hospital costs were calculated by multiplying the
number of AP-DRG cases [11] by the average costs of AP-
DRG cases [14]. As AP-DRG cost weights do not cover
total costs of hospitalisations (investments in hospital infra-
structure and additional costs of patients with private and
semi-private insurance coverage are not covered), we es-
timated a correction factor by dividing total AP-DRG costs
by total costs of hospitalisations according to the Statistics
on Costs and Financing of Health Care [27]. Cost of inpa-
tient rehabilitation was calculated by multiplying the num-
ber of days of stay by the average daily tariff for cardiac
rehabilitation [18].
Outpatient costs were costs incurred in 2008 as well as
costs of surviving patients for the rest of their life. Costs
leading to hospitalisation included transport by ambulance
(van and helicopter [number and price of ambulance flights
for patients with ACS were provided by Rega, Swiss Air
Rescue, and are based on the Rega statistics for 2008. Costs
of transport by ambulance van are based on sample in-
voices and interviews with the emergency services of the
Zurich metropolitan area; Schutz und Rettung Zürich]) and
the emergency services of the cantonal hospital of Win-
terthur (the second city in the canton of Zurich). The rep-
resentativeness of these costs for the whole of Switzerland
was verified by an expert of the national confederation of
emergency services (Interverband für Rettungswesen)) and
visits to a general practitioner (GP) or cardiologist. Costs
after hospital discharge included visits to GPs and cardiolo-
gists, diagnostic interventions, medication and outpatient
rehabilitation. The number of GP and cardiologist visits
and annual ECGs was assessed in expert interviews. Types
of drugs used were derived from a German Study [19]. The
proportion of STEMI, NSTEMI and UAP patients who use
these drugs was obtained from the AMIS plus registry [17].
Daily doses were assumed to be WHO defined daily doses
[28]. A cardiologist and a GP gave advice on the selec-
tion of products for each type of drugs. The number of pa-
tients in outpatient rehabilitation programmes was based
on AMIS Plus [17]. Prices of outpatient services were ob-
tained from official price lists and through direct inquiry to
service providers [18, 29, 30].
Production losses included absenteeism (temporary ab-
sence from work), permanent disability and premature
death and the data were derived from relevant databases
from the Swiss Federal Statistic Office as referenced.
Losses were calculated for individuals of working age and
considered degree of labour force participation [15], activ-
ity level [15] and median gross salary [16]. Production
losses due to absenteeism were estimated on the basis of
a previous Swiss study [5] and three studies carried out
in similar countries [31–33]. Production losses due to per-
manent disability were estimated on the basis of statements
by a cardiologist working centre specialised in medical ex-
aminations for the Swiss Disability Insurance Fund and a
private practice cardiologist.
Intangible costs were calculated on the basis of the number
of individuals affected by ACS (by age, gender, surviving
or not) using quality of life weights of cardiovascular dis-
eases recently estimated for England [34].
Future costs and QALY losses were discounted to present
value at a 2% rate corresponding to the real interest rate on
long term Swiss government bonds over the past 20 years
[35, 36]. An extreme value sensitivity analysis was carried
out with regard to the lower and upper bounds of prices and
the discount rate.
Results
Number of patients with ACS events and type of ACS
event
Table 1 gives an overview of the number of ACS events in
2008 by type of ACS event and sequence of hospital stays
of patients. According to MedStat data a total of 13,231 pa-
tients had at least one hospital stay, including 102 patients
with stroke as the primary diagnosis and ACS as the sec-
ondary diagnosis. A total of 2,752 patients died due to ACS
Original article Swiss Med Wkly. 2012;142:w13655
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according to DeathStat data. To avoid double counting we
subtracted 1,028 patients who died in the course of a hos-
pital stay and are thus included in the MedStat as well as
in the DeathStat. This lead to a total number of 14,955 in-
dividuals who suffered from ACS in 2008. The 13,231 pa-
tients with at least one hospital stay had a total of 19,064
inpatient stays.
Figure 2 shows the age of patients treated in hospital. From
the total number of patients, 8,885 were men (67.2%) and
4,346 were women (32.8%). The mean age was 68.4 years
for the hospitalised patients (men 65.6, women 74.2) and
79.3 years for those who died in hospital (men 76.8, wo-
men 82.1). The mean age of all deaths was 77.9 years (men
74.3, women 82.8).
Figure 2
Age at ACS event leading to hospital stay in 2008. Own calculation
on the basis of MedStat [11].
Figure 3
Average length of stay in acute care by single stay and by patient
(2002–2008).
Own calculation on the basis of MedStat [11]. Average length of
stay per patient is higher than average length of single stays as
many patients have multiple stays in the course of their ACS
treatment (e.g. when a patient is transferred from one hospital to
another for specialised care).
Figure 4
Number of ACS patients by main diagnosis at first hospital stay per
year (2002–2008). Own calculation on the basis of MedStat [11].
Table 2 shows the evolution of the number of patients in
acute hospital care by type of ACS from 2002 to 2008
according to MedStat. The total number of patients in-
creased by 10.9%, with UAP patients decreasing by 36.8%
and NSTEMI patients increasing by 75.1%. These changes
were probably due to the introduction of more accurate dia-
gnostic procedures.
Figure 4 shows the evolution of the average length of stay
of single acute care hospital stays and across-hospital
length of stay by single ACS patients in a given year from
2002 to 2008 according to MedStat. Average across-hos-
pital length of stay was higher than the average length of
single stays as many patients have multiple stays in the
course of their treatment, for example when a patient is
transferred from one hospital to another for specialised
care. While the average length of a single stay decreased by
nearly 2 days in these 7 years (UAP: –1.8 days, NSTEMI
–1.94 and STEMI –1.69) the average across-hospital length
of stay decreased by only 1.08 days. This difference was
probably due to an increased cooperation between hospitals
in the treatment of ACS patients.
Figure 5 shows in-hospital mortality due to ACS per hos-
pital stays and patients. As expected, mortality per patient
increased with severity of ACS from 1.39% for UAP pa-
tients to 9.64% for STEMI patients. Mortality rates per pa-
tient were substantially higher than mortality rates per stay.
The average life expectancy for surviving patients was re-
duced by 2.8 years for men and by 2.3 years for women due
to the increased relative risk of mortality (average age of
survivors: men 64.8 years, women 73.3 years; average ex-
pected remaining life years: men 15.6 years, women 12.9
years).
Direct costs
The average length of hospital stays was 4.8 days for UAP
patients, 8.3 days for NSTEMI patients, 7.3 days for
STEMI patients and 7.19 days for all ACS patients (table
3). Considering the sequence of stays in different hospitals
that may be part of a same treatment sequence, the average
length of stay per patient was 5.6 days for UAP patients,
10.7 days for NSTEMI patients, 9.7 days for STEMI pa-
Figure 5
Total direct cost of ACS in Switzerland in 2008 – societal
perspective (%). Own calculation on the basis of a variety of
sources.
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tients and 9.12 days for all ACS patients. Average hours in
intensive care unit (ICU) per patient ranged from 7.0 hours
for UAP patients to 26.3 hours for STEMI patients.
Inpatient hospital costs were calculated by multiplying the
number of ACS patients associated to single AP-DRG
codes by the average costs of these AP-DRG cases [14]
(an example: 1,729 NSTEMI stays are linked to the AP-
DRG code number 122 for “circulatory disturbance with
acute MI without cardiovascular complications, without
fatal consequences” according to MedStat data 2008. The
average cost-weight of AP-DRG code number 122 is CHF
8,999 [14]. By multiplying the number of AP-DRG cases
by their average cost weight we obtain an inpatient treat-
ment cost of CHF 15,559,721 for these NSTEMI patients).
The resulting CHF 230 Mio was multiplied by a factor of
1.173. The factor is calculated by dividing total acute care
hospital cost (without psychiatric and rehabilitation clinics)
of CHF 13,739 Mio according to FSO [27] by total acute
care hospital treatment cost of CHF 11,711 Mio calculated
with the AP-DRG weights provided by FSO [14] and the
total cost of inpatient acute care thus amounted to CHF 270
Mio.
A total of 2,249 inpatient rehabilitation stays with an aver-
age length of stay of 22.5 days were recorded in MedStat.
The resulting 50,577 inpatient days were multiplied by the
average costs of cardiac rehabilitation (CHF 565 for basic,
CHF 659 for semi-private and CHF 748 for private insur-
ance) according to relative weights of the insurance cover-
age of the patients retrieved from MedStat. The total cost
of inpatient rehabilitation amounted to CHF 30 Mio.
A total of 4,115 patients (21.6%) reached the hospital by
ambulance and 6,739 (35.3%) had a previous emergency
GP or cardiologist visit. A total of 509 helicopter flights
were carried out for ACS patients. Prices were CHF 1,618
for ambulance transport, CHF 3,752 for a helicopter ambu-
lance flight and CHF 237 for a typical GP or cardiologist
visit prior to hospitalisation.
As MI patients usually need more post-hospital care than
UAP patients, costs were calculated separately based on the
information contained in table 4.
Table 5 gives an overview of daily doses, daily prices and
percentages of the patients taking the drugs and the re-
spective sources. Total drug costs per patient amounted
to CHF 1,367 (UAP), CHF 1,385 (NSTEMI) and CHF
1,459 (STEMI) in the first year after the ACS event and
to CHF 1,422 (UAP), CHF 1,441 (NSTEMI) and CHF
1,518 (STEMI) from the second year on (drug prices 1 May
2011).
Total direct costs of ACS amounted to CHF 630 Mio.
Table 6 and figure 5 give an overview of the composition
of costs by type of costs and perspective. Inpatient and out-
patient costs each represent approximately half of total dir-
ect costs. Social and private health insurance covers CHF
462 Mio or 73% of total costs.
Table 7 shows the structure of total direct costs and average
direct costs per patient over the three ACS event types.
Average direct costs per patient amounted to CHF 47,589
and varied between CHF 40,207 for UAP patients and CHF
52,135 for STEMI patients. These costs can be interpreted
as direct costs potentially avoided by an intervention pre-
venting an ACS event.
Production losses
In 2008 427 individuals died due to ACS before reaching
retirement age (369 men, 58 women). The average number
of years to retirement was 9.63 years. The total number of
1,656 full time equivalent work years lost corresponded to
a total loss due to premature death of CHF 312 Mio.
Table 1: Number of patients with ACS and number of inpatient stays due to ACS in 2008.
Own calculation on MedStat [11] and DeathStat [12]. The table on the left shows all hospital and inpatient rehabilitation stays in 2008. Many patients experience multiple
stays in the course of ACS treatment (e.g., transfer to other hospital or rehabilitation clinic). A total of 4,294 patients had, for example, 2 or more stays. No patient has a
rehabilitation stay as first treatment, as inpatient rehabilitation stays due to ACS can only be identified if preceded by a hospital stay in the same year. The table on the right
shows the calculation of the total number of patients with at least one inpatient treatment. The 1,028 patients deceased in hospital have to be subtracted in order to avoid
double counting.
Sequence
of stay
UAP NSTEMI STEMI Rehab Total Calculation of total number of patients with ACS
1 2,884 4,818 5,529 0 13,231
2 341 1,067 1,427 1,459 4,294
13,231 Total of patients with at least one ACS event according to MedStat.
3 60 213 330 605 1,208 –1,028 Of which died in hospital (MedStat)
4 19 43 50 152 264
5 6 10 8 24 48
2,752 Number of fatalities due to ACS (DeathStat).
6 3 4 1 4 12
7 0 1 0 3 4
8 0 1 0 1 2
9 0 0 0 1 1
Total 3,313 6,157 7,345 2,249 19,064
14,955 Patients with at least one ACS event in 2008
Table 2: In-hospital mortality due to ACS in 2008 (per stays and per patient).
Own calculation on MedStat [11]. In-patient hospital stays include at least 1 night spent in hospital. Deaths occurring in the emergency room are thus excluded from this
number.184 patients died during the first day of stay. Mortality rates differ significantly if calculated per number of stays or number of patients.
Dimension UAP NSTEMI STEMI Rehab Total
Number of deaths 40 432 533 23 1,028
Number of stays 3,313 6,157 7,345 16,815
Number of patients 2,884 4,818 5,529 13,231
Mortality stays (%) 1.21 7.02 7.26 6.11
Mortality patients (%) 1.39 8.97 9.64 7.77
Original article Swiss Med Wkly. 2012;142:w13655
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 5 of 13
A total of 5,149 individuals below retirement age survived
an ACS event (4,194 men, 955 women). Based on four
studies [5; 31–33] we estimated that on average 3 months
of work were lost by economically active survivors. Res-
ulting total losses due to absenteeism amounted to CHF 79
Mio.
Based on information from cardiologists we estimated that
5% of the surviving patients were affected by permanent
disability and that the average degree of disability was
60%. Production losses for an estimated 151 patients with
permanent disability were CHF 128 Mio.
Total production losses thus amounted to CHF 519 Mio at
present value.
Intangible costs
ACS led to 2,752 deaths in 2008. The 12,203 patients sur-
viving an ACS also faced an increased relative risk of mor-
tality of 1.5. Inserting information on age, gender and life
expectancy of these individuals in the equation on QALY
Table 3: Average length of stay in acute care hospital and average hours in ICU of ACS patients in 2008 (per stay and per patient).
Own calculation on MedStat [11]. Length of stay differs significantly if calculated per number of stays or number of patients.
UAP NSTEMI STEMI all ACS
Average number of days of inpatient care
Per stay 4.85 8.35 7.27 7.19
Per patient 5.57 10.65 9.64 9.12
Average number of hours of ICU care
Per stay 6.06 14.41 19.78 15.11
Per patient 6.97 18.43 26.28 19.21
Table 4: Outpatient resource use after hospital discharge.
Quantity Price (CHF)
UAP NSTEMI STEMI
Source of
information
Leaving hospital alive 2,844 4,386 4,996 MedStat [11]Number of patients
Alive 1 year after event 2,702 4,098 4,959 MedStat [11],
own calc.
GP visit after hospitalisation (including
diagnostic tests)
100% of pat
3 in 1st year
1 from 2nd year on
236.29
per visit
[19], expertsa
80% of patCardiologist visit after hospitalisationb
(including diagnostic tests) 1 in 1st year
1 in 2nd year
0.5 from 3d year
on
1.5 in 1st year
1 in 2nd year
0.5 from 3d year
623.88
per visit
[19], expertsa
Longtime-ECGc 1 in 1st year
(20% of pat)
1 in 2nd year (5%
of pat)
1 in 1st year (30% of pat)
1 in 2nd year (20% of
pat)
1 from the 3d year on
(10% of pat)
225.84
per ECG
[19], expertsa
Outpatient rehabilitation 10.4% of pat 19.6% of
pat
17.6% of pat 2,700 per
package
AMIS Plus
registry [17]
Outpatient heart-groupsd (lifelong outpatient
heart group)
5% of pat 10% of pat 799.15
per year
Expertsa, e
Outpatient services
(frequency of use and share of
patients using service)
Drugs See table 5
pat = patients; a interviews on typical outpatient treatment patterns were carried out with a private practice cardiologist and private practice general practitioner in
Winterthur, a mid-sized town in the German speaking part of Switzerland; b cardiologist is additional to GP; c longtime-ECG is additional to GP and cardiologist; d outpatient
rehabilitation programmes are usually offered in packages of 36 training sessions over 6 to 12 weeks (Ambulante Herzrehabilitation Zürich, Klinik Gais (Appenzell), Spital
Männedorf, Herz Zentrum Hirslanden; Zürich); e interview with the “Heart Group Team” of the Swiss Heart Foundation.
Table 5: Medication after an ACS event.
Own calculation on the basis of AMIS Plus data [17], list of pharmaceutical specialties [35] and WHO Collaborating Centre for Drug Statistics Methodology [17]. Drug
prices 1st of May 2011.
Drug; price per package Patients taking medicine (%) WHO defined daily dose (mg) Price per daily dose (CHF)
Beta Blocker
Metoprolol-Mepha ZOK 100 mg; 100 depotabs, CHF 40.1
Metoprolol-Mepha ZOK 50 mg; 100 depotabs, CHF 28.2
79.2 150 0.60
ACE Inhibitor
Accupro 10; 100 tablets (divisible), CHF 46.90
64.5 15 0.70
ATII-Antagonist
Cosaar 50; 98 tablets (divisible), CHF 111.10
15.4 50 1.13
Statins
Simvastin-Mepha Lactab 20; 100 tablets (divisible), CHF 97.20
91.7 30 1.46
Platelet aggregation inhibitor
Plavix 75; 84 tablets, CHF 140.90
84.2 75 1.68
Platelet aggregation inhibitor, Cox-1/Cox-2 Inhibitor
Aspirin Cardio 100; 100 tablets, CHF 16.15
96.0 100 0.16
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weights proposed by Ara and Brazier [34], we obtained a
total of 36,438 QALYs lost due to premature death (19,950
QALYs for death due to ACS in 2008,16,488 QALYs for
increased mortality in remaining life years).
Ara and Brazier [34] also estimate a 0.395 QALY loss for
the first year after a MI and a QALY loss of 0.090 if more
than 12 months have passed since the event. As QALY
weight after UAP is not specified, we used the same val-
ues as for MI patients. Applying these values to the patients
surviving an ACS we obtained a loss of 13,440 QALYs due
to reduced quality of life.
Total intangible costs in terms of life years lost and quality
of life lost thus amounted to 49,878 QALY at present value.
Sensitivity analysis
The results of the sensitivity analysis showed that our es-
timation of the direct costs of ACS is robust to variations
of the assumed prices, the interest rate and the factor for in-
creased relative risk of mortality after ACS. Table 8 shows
that the results change by –11% or +14% when varying
prices to the lower or upper bound of the mean cost of
AP-DRGs and the lower or upper bound of the prices cal-
culated for single health care resources. Results change to
+8% or –6% when changing the discount rate to 0% or 4%
instead of the 2% of the base scenario. Assuming a factor
for increased relative risk of mortality after ACS of 1.0 in-
stead of 1.5 increases direct costs by 7% as surviving pa-
tients live longer and thus have more years with outpatient
follow-up costs. A relative risk factor to 2.0 leads to a 5%
decrease in costs.
Discussion
We assessed the costs of ACS in Switzerland in 2008 from
a societal and health insurance perspective with a bottom-
up incidence-based approach. To our knowledge, this study
provides the first estimate of the total costs of ACS in
Switzerland. Total direct costs amounted to CHF 630 Mio
for the society and CHF 462 Mio for health insurers. Pro-
duction losses amounted to CHF 515 Mio and intangible
costs to 49,878 QALYs lost. Average total direct costs and
production losses per patient were CHF 86,813. Results ap-
pear robust in the sensitivity analysis.
In a prevalence based COI study of ischaemic heart dis-
ease, Sagmeister et al. [6] estimated direct costs of CHF
14.6 Mio and production losses of CHF 16.7 Mio per
Table 6: Total direct cost of ACS occurring in Switzerland in 2008 (CHF).
Own calculation, present value of future costs calculated at 2% discount rate.
Societal perspective Health insurance perspective
CHF % of total Social insurance Private insurance Total
Outpatient before hospital
Ambulance 7,743,988 1.2 2,899,636 1,507,811 4,407,447
Consultation GP 1,595,930 0.3 1,595,930 1,595,930
Total 9,339,918 1.5 4,495,566 1,507,811 6,003,376
Inpatient cost
Acute care hospital 270,344,657 42.9 96,896,030 24,722,106 121,618,136
Inpatient rehabilitation 30,285,424 4.8 12,870,231 1,684,854 14,555,085
Total 300,630,081 47.7 109,766,261 26,406,960 136,173,221
Outpatient after hospital
1st year 41,484,489 6.6 41,268,121 216,368 41,484,489
2nd year 26,650,997 4.2 26,432,912 218,085 26,650,997
From 3rd year on 251,542,174 39.9 249,172,280 2,369,894 251,542,174
Total 319,677,660 50.8 316,873,313 2,804,347 319,677,660
Total direct costs 629,647,658 100.0 431,135,140 30,719,118 461,854,258
Table 7: Total direct cost and average direct cost over ACS event types (CHF).
Own calculation, present value of future costs calculated at 2% discount rate.
UAP % NSTEMI % STEMI % Total %
Outpatient before hospital
Ambulance 1,006,812 0.9 2,907,524 1.3 3,829,651 1.3 7,743,988 1.2
Consultation GP 278,398 0.2 593,553 0.3 723,978 0.3 1,595,930 0.3
Total 1,285,211 1.1 3,501,077 1.6 4,553,630 1.6 9,339,918 1.5
Inpatient cost
Acute care hospital 34,279,245 29.6 105,270,223 46.7 130,795,189 45.4 270,344,657 42.9
Inpatient rehabilitation 7,263,405 6.3 10,831,393 4.8 12,190,626 4.2 30,285,424 4.8
Total 41,542,649 35.8 116,101,616 51.5 142,985,816 49.6 300,630,081 47.7
Outpatient after hospital
1st year 8,362,428 7.2 15,440,700 6.8 17,681,361 6.1 41,484,489 6.6
2nd year 9,244,059 8.0 11,557,848 5.1 5,849,090 2.0 26,650,997 4.2
From 3rd year on 55,523,096 47.9 78,836,220 35.0 117,182,858 40.7 251,542,174 39.9
Total 73,129,582 63.1 105,834,768 46.9 140,713,309 48.8 319,677,660 50.8
Total direct costs 115,957,443 18.4 225,437,461 35.8 288,252,754 45.8 629,647,658 100.0
Average cost per patient
Overall 40,207 46,791 52,135 47,589
In 1st year 17,750 28,029 29,883 26,563
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100,000 individuals for Switzerland in 1993 (Sagmeister et
al. [6] report mean direct costs of USD 9.9 Mio and pro-
duction losses of USD 11.3 Mio per 100,000 individuals
calculated at an exchange rate of 1.4776 CHF/USD). Extra-
polating from these numbers to the total population in 2008
we obtained direct costs of CHF 1,124 Mio and production
losses of 1,286 Mio. A direct comparison of these results is
not possible, as these studies do not cover exactly the same
illnesses and costs are not adjusted for inflation. A study
by Bramkamp et al. [37] based on AMIS Plus data between
1997 and 2005 estimates inpatient costs of ACS patients at
CHF 18,757 (Bramkamp et al. [37] report a mean cost of
EUR 12,101 calculated at an exchange rate of 1.55 CHF/
EUR) per hospital stay while in our study hospitalisation
costs amounted to CHF 16,078 per ACS hospital stay (CHF
17,484 per MI hospital stay).
A comparison with gross domestic product (GDP) and total
healthcare expenditure is useful to understand the mag-
nitude of costs. As our study estimates the lifetime costs
of patients with an ACS occurring in 2008, which include
costs incurring in the subsequent years, these costs cannot
be directly compared with total healthcare costs in 2008.
However, a comparison with current health care costs can
be made under the assumption that the composition of ACS
events determined for 2008 (fig. 1) is similar to the com-
position of ACS events in the years before 2008. Under
this assumption the outpatient costs for ACS patients in
2008 for patients with their first ACS event before 2008
are represented by the future costs of patients with a first
ACS event in 2008. As the future costs are reinterpreted as
current costs, they must not be discounted and total direct
costs thus amount to CHF 683 Mio in 2008 (table 8). In
this prevalence-based estimate, the direct costs of ACS thus
amount to 1.17% of total health expenditures in Switzer-
land [27]. The undiscounted sum of total direct costs and
total productivity losses amount to CHF 1,247 Mio and
correspond to 0.23% of Swiss GDP in 2008 (undiscounted
production losses amounted to CHF 563 Mio).
Comparison with similar cost studies in similar
countries
Our results are in a similar range to the costs of ACS
in other European countries. According to Taylor et al.
[38] direct costs for the treatment of ACS corresponded
to 1.41% of health expenditures in Germany, 1.96% in the
UK, 0.73% in France and 2.54% in Italy in 2004. Brüggen-
jürgen et al. [19] estimated total yearly costs of MI patients
in Germany in 2004 at EUR 11,672 per patient (18,015
CHF at 2004 exchange rate). A recent study by Kanichay
et al. [39] estimated costs of ACS at 0.45% of health ex-
penditure in France, 1.25% in Italy and 0.41% in the UK in
2009. These costs do not include outpatient consultations.
Average costs per hospitalisation due to MI are calculated
to be CHF 8,995 in France and CHF 7,627 in Italy (calcu-
lated at 1.509 CHF/EUR rate). These costs do not include
costs for expensive drugs and medical procedures and rep-
resent a lower bound of hospital treatment costs of ACS.
Kanichay et al. [39] estimated productivity losses due to
ACS in 2009 as percentage of GDP at 0.07% in France,
0.09% in Italy and 0.22% in UK. These estimates are in
the same order of magnitude as our estimate of productiv-
ity losses at 0.1% of Swiss GDP.
Strengths and limitations
The first strength of the study is the accurate distinction
between the number of hospital stays due to ACS and the
number of patients hospitalised due to ACS. Although the
treatment of a single ACS event is frequently composed
of a sequence of hospitalisations, the number of hospitals
stays due to ACS is often considered equivalent to the num-
ber of patients with an ACS event. An example is the num-
ber of 15,404 MI patients in 2008 calculated by the Swiss
Health Observatory (200 MI cases per 100,000 residents
adjusted to population of 7.7 Mio in 2008) [40] which is
considerably higher than our calculation of 12,103 MI pa-
tients in 2008 (10,347 MI patients according to MedStat
[sum of NSTEMI and STEMI patients in first line of table
1] minus 965 in-hospital deaths of MI patients according
to MedStat plus 2,721 death due to MI according to
DeathStat). As a consequence of the lower number of pa-
Table 8: Results of sensitivity analysis on direct costs. Assumed factor for increased relative risk of mortality: 1.5; assumed discount rate: 2%.
Direct cost in Mio. CHF Deviation from base scenario (%)
Price scenario Price scenario
Low Base High Low Base High
0% 606 683 785 0% –4% 8% 25%
1% 582 654 749 1% –8% 4% 19%
2% 561 630 720 2% –11% 0% 14%
3% 543 608 694 3% –14% –3% 10%
Discount rate
4% 527 590 672
Discount rate
4% –16% –6% 7%
Direct cost in Mio. CHF Deviation from base scenario (%)
Price scenario Price scenario
Low Base High Low Base High
1.0 600 676 776 1.0 –5% 7% 23%
1.5 561 630 720 1.5 –11% 0% 14%
RR
2.0 534 598 681
RR
2.0 –15% –5% 8%
RR = factor for increased relative risk of mortality.
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tients we also obtained considerably higher in-hospital
mortality rates of ACS patients. While the in-hospital mor-
tality rate is 4.8% for NSTEMI patients and 6.9% for
STEMI patients according to AMIS Plus data [17], we cal-
culated in-hospital mortality rates of 9.0% for NSTEMI
patients and 9.6% for STEMI patients (see). This higher
mortality may also be due to the higher average age of
the MedStat population (NSTEMI: 71.1 years, STEMI:
66.3 years) in comparison with the average age of the
AMIS Plus population (NSTEMI: 67.2 years, STEMI: 64.5
years). The more accurate distinction between number of
hospital stays due to ACS and patients hospitalised leads to
higher costs per patient as multiple hospital stays are now
correctly assigned to the same patient. A second strength is
the accurate use of all publicly available data in Switzer-
land to take account of the costs of ACS in different cost
categories and from a societal and a health insurance per-
spective.
Several limitations have to be mentioned. First, we did not
include follow-up costs of heart failure due to coronary
heart disease, as this was not the specific focus of our
study. Even though heart failure can also be caused by other
underlying diseases, such as hypertension or myocardit-
is, coronary heart disease is the most important reason for
chronic myocardial dysfunction. Much research has been
done concerning the economic consequences of heart fail-
ure and the costs are estimated to be in a range of 2% to 4%
of total health care expenditures in developed countries [3].
A recent study of the burden of ACS in Europe discussed
this topic and decided not to quantify these costs [36]. The
reported costs of ACS in our study are thus a conservat-
ive estimate. Second, we have no direct estimate to guess
the coding quality of the public databases used. It is well
known, for example, that death certificates often have lim-
ited quality concerning the documented disease leading to
death. However, in the absence of more valid data, use of
death certificates or publicly available hospital statistics is
an accepted information source for cost-of-illness studies.
Third, some of the costs of ACS were not considered, such
as the assistance of family and friends.
Conclusion
The main results of this study are an accurate description
of the structure of hospitalisation and treatment sequences
of patients with ACS and a detailed calculation of the con-
siderable costs of ACS in terms of direct medical expendit-
ures, lost production and premature death, even without
taking into account costs for its chronic consequences such
as congestive heart failure. These results may serve as a
basis for health policies and as an input for health econom-
ic models of cost effectiveness of new treatments of ACS.
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Figures (large format)
Figure 1
Overview of ACS events and outpatient treatments considered.
The figure gives an overview of ACS events occurring in 2008 and resulting treatments. All inpatient treatments in 2008 were considered as well
as outpatient treatments from ACS in 2008 until death. Remaining life years of surviving patients were modelled on age, gender and life
expectancy statistics adjusted by a factor for increased relative mortality risk after an ACS. Treatments considered in the study are represented
by bold icons and continuous lines, treatments not considered by light icons and broken lines. The study did not consider inpatient care provided
in 2009 and following years (example 3) or possible outpatient treatment before a 1st ACS event in 2008 (example 5).
Examples of sequences of ACS events:
1 – Death at 1st event in 2008 before reaching hospital.
2 – Hospital stay at 1st event in 2008 and death at 2nd event in 2008. Outpatient care between 1st event and death.
3 – Hospital stay at 1st event in 2008 and 2nd event in 2010 (not considered in study). Outpatient care until death.
4 – 1st event in 2008: Sequence of 2 hospital stays. Outpatient care until death.
5 – Hospital stay at 1st event in 2007 (not considered). Hospital stay at 2nd event in 2008. Outpatient care until 2nd event in 2008 not
considered. Outpatient care until death.
6 – Hospital stay at 1st event in 2006 and 2nd event in 2009 (both not considered). Outpatient care from 1st event in 2006 until death in 2010
not considered.
Figure 2
Age at ACS event leading to hospital stay in 2008. Own calculation on the basis of MedStat [11].
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Figure 3
Number of ACS patients by main diagnosis at first hospital stay per year (2002–2008). Own calculation on the basis of MedStat [11].
Figure 4
Average length of stay in acute care by single stay and by patient (2002–2008).
Own calculation on the basis of MedStat [11]. Average length of stay per patient is higher than average length of single stays as many patients
have multiple stays in the course of their ACS treatment (e.g. when a patient is transferred from one hospital to another for specialised care).
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Figure 5
Total direct cost of ACS in Switzerland in 2008 – societal perspective (%). Own calculation on the basis of a variety of sources.
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